Study Confirms Effectiveness of Groundbreaking Penn Cancer Treatment

Now, go re-read Philly Mag’s “Patient Number 7.”

A Penn/CHOP study released over the weekend confirmed that a groundbreaking new cancer treatment being tested by a group of Penn researchers has yielded a very high success rate.

Penn and Children’s Hospital of Philadelphia on Saturday reported the results from 59 adults and children who received a gene therapy engineered from their own disease-fighting T cells to treat recurrent, intractable leukemia.

In 31 patients – more than half – the leukemia disappeared. The “serial killer” T cells kicked in within two weeks of being infused, eradicating pounds of malignant cells within days. Twenty-six patients remain cancer-free, including two of the first three who were treated in 2010.

Caveat: The T-cell treatment is better at treating “acute lymphoblastic leukemia (ALL), the most common form in children,” than “against chronic lymphocytic leukemia (CLL), the slower-progressing form that arises in adults.” For much, much more check out Jason Fagone’s “Patient Number 7,” on the treatment and the men behind it.


Around the Web

Be respectful of our online community and contribute to an engaging conversation. We reserve the right to ban impersonators and remove comments that contain personal attacks, threats, or profanity, or are flat-out offensive. By posting here, you are permitting Philadelphia magazine and Metro Corp. to edit and republish your comment in all media.